Casein Kinase II Inhibitor I

A cell-permeable, highly selective, ATP/GTP-competitive casein kinase II (CKII) inhibitor (IC₅₀ = 900 nM and 1.6 µM for rat liver and human recombinant CKII, respectively) and DYRK (IC₅₀<1 µM for DYRK1a). Specificity for CKII has been reported following the screening of 33 kinases, including PKA, Akt, PKC, MKK1, ERK2, p38, JNK, Lck, Lyn, and Syk. Also reported to inhibit NS3-associated viral helicase activity in hepatitis C virus (HCV) (IC₅₀ = 20 and 60 µM using DNA and RNA substrates, respectively) and West Nile virus (WNV) (IC₅₀ = 1.7 µM and 900 nM using DNA and RNA substrates, respectively).

Cell permeable: yes

Primary Target
CK2 rat liver, human recombinant

Product competes with ATP.

Reversible: yes

Target IC₅₀: 900 nM and 1.6 µM, using rat liver and human recombinant CK2, respectively

Packaged under inert gas

Toxicity: Carcinogenic / Teratogenic (D)

A 10 mM (5 mg/1.15 ml) solution of Casein Kinase II Inhibitor I (Cat. No. 218697) in DMSO.

Following initial use, aliquot and refrigerate (4°C).

Single spot by TLC

Borowski, P., et al. 2003. Eur. J. Biochem.270, 1645.
Zien, P., et al. 2003. Biochem. Biophys. Res. Commun.306, 129.
Sarno, S., et al. 2003. Biochem. J.374, 639.
Sarno, S., et al. 2001. FEBS Lett.496, 44.
Szyszka, R., et al. 1995. Biochem. Biophys. Res. Commun.208, 418."

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany